AstraZeneca (LON:AZN) Given Sell Rating at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reissued by equities research analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Wednesday,Digital Look reports. They currently have a £115 target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential downside of 15.29% from the company’s current price.

Other research analysts also recently issued reports about the stock. Shore Capital Group reissued a “buy” rating on shares of AstraZeneca in a research report on Friday, January 16th. Berenberg Bank boosted their price objective on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Jefferies Financial Group reissued a “buy” rating and set a £180 price objective on shares of AstraZeneca in a research report on Friday, April 10th. Citigroup boosted their price objective on shares of AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research report on Friday, April 10th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of £153.33.

AstraZeneca Trading Up 1.8%

AstraZeneca stock traded up GBX 246 during mid-day trading on Wednesday, reaching £135.76. 154,623,859 shares of the company traded hands, compared to its average volume of 31,940,236. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The firm’s 50 day moving average price is £146.29 and its 200 day moving average price is £139.94. The firm has a market capitalization of £210.54 billion, a price-to-earnings ratio of 20.45, a P/E/G ratio of 0.86 and a beta of 0.28. AstraZeneca has a 52-week low of GBX 9,651 and a 52-week high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.